Scarica l'app Stockscreener
8.29
5.85%
-0.515
Dopo l'orario di chiusura:
8.39
0.10
+1.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Precedente Chiudi:
$8.805
Aprire:
$8.34
Volume 24 ore:
8.57M
Relative Volume:
1.95
Capitalizzazione di mercato:
$2.12B
Reddito:
$885.72M
Utile/perdita netta:
$-457.98M
Rapporto P/E:
-4.6665
EPS:
-1.7765
Flusso di cassa netto:
$293.05M
1 W Prestazione:
-17.84%
1M Prestazione:
-15.75%
6M Prestazione:
-5.26%
1 anno Prestazione:
+3.50%
Intervallo 1D:
$8.045
$8.46
Intervallo di 1 settimana:
$8.045
$10.10
Portata 52W:
$6.00
$11.22
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Nome
Biocryst Pharmaceuticals Inc
Settore
Telefono
919-859-1302
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.29 | 2.25B | 885.72M | -457.98M | 293.05M | -1.7765 |
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 58.15B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.35 | 42.94B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.86 | 30.29B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
503.86 | 21.74B | 3.17B | 1.29B | 1.01B | 27.09 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-18 | Ripresa | Evercore ISI | Outperform |
| 2025-10-15 | Ripresa | TD Cowen | Buy |
| 2025-10-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Iniziato | Wedbush | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-09-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-02-22 | Aggiornamento | Needham | Hold → Buy |
| 2022-11-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-08-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Overweight |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-05-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Ripresa | Piper Jaffray | Overweight |
| 2018-08-08 | Ripresa | JP Morgan | Overweight |
| 2018-07-17 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Iniziato | Seaport Global Securities | Neutral |
| 2018-01-02 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Iniziato | Barclays | Equal Weight |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-02-16 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-08-12 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | FBR Capital | Outperform |
| 2016-02-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Downgrade | Needham | Buy → Hold |
Mostra tutto
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
BCRX: Biocryst Pharmaceuticals Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
BCRX Downgraded by RBC Capital -- Price Target Lowered to $11.00 - GuruFocus
BCRX Looks 24.9% Undervalued on GF Value™ Despite Unprofitabilit - GuruFocus
BioCryst Pharma (BCRX): ORLADEYO Growth And Pipeline Catalysts Shape The Long-Term Outlook - RTTNews
Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs? - Stocktwits
BioCryst's Orladeyo Approved for HAE Attack Prevention - Intellectia AI
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Stocktwits
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - The Manila Times
BCRX Reiterated by Needham -- Price Target Maintained at $16 - GuruFocus
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook - Investing.com Canada
BCRX Should I Buy - Intellectia AI
(BCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
C5 inhibitors disclosed in Biocryst patents - BioWorld News
BioCryst to Present at Upcoming Investor Conference - marketscreener.com
BioCryst stock holds firm after a Q2 revenue beat - ad-hoc-news.de
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset - Stocktwits
BioCryst Pharmaceuticals Inc. (BCRX) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet - finance.yahoo.com
BCRXRevenue by Segment - Quiver Quantitative
Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm
BioCryst gets Japan approval for HAE drug in young children By Investing.com - Investing.com South Africa
BioCryst Pharmaceuticals Announces Japan Approval of ORLADEYO for Pediatric HAE Prophylaxis - Quiver Quantitative
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan - The Manila Times
BioCryst gets Japan approval for HAE drug in young children - Investing.com
BioCryst Pharmaceuticals (BCRX), What Is Behind The Fresh Attention Now? - Sahm
NFJ Investment Group LLC Makes New $2.79 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Passes Minervini Trend Template and High-Growth Momentum Screen - ChartMill
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
BioCryst (BCRX) Quarterly Figures: Reported EPS Tops Expectations in the Latest Reading; Price Reaction: The Share Price Adds 3.81% at the CloseEarnings Growth Analysis - Vinanet
BioCryst (BCRX) Financial Update: EPS Exceeds Its Estimate in Latest Trading; Post-Report - vinanet.vn
Rice Hall James & Associates LLC Takes $23.32 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
What is HC Wainwright's Forecast for BCRX Q3 Earnings? - MarketBeat
How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares - simplywall.st
Discipline and Rules-Based Execution in BCRX Response - Stock Traders Daily
Biocryst Pharmaceuticals Stock Price Forecast. Should You Buy BCRX? - StockInvest.us
RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares - Stock Titan
Research Analysts Issue Forecasts for BCRX Q4 Earnings - MarketBeat
Wedge Capital Management L L P NC Acquires Shares of 380,801 BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.7%Here's What Happened - MarketBeat
Biocryst Pharmaceuticals Inc. (BCRX) News, Articles, Events & Latest Updates - Stocktwits
Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update? - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain - Yahoo Finance
Bank of America Corp DE Buys 3,556,208 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst (BCRX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High? - Yahoo Finance
A Look at BioCryst Pharmaceuticals Inc (BCRX) After 5.1% Gain -- GF Value $12.76 vs Price $10.35 - GuruFocus
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6%What's Next? - MarketBeat
Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.56%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):